Macrogenics (MGNX) Total Non-Current Liabilities (2012 - 2026)
Macrogenics (MGNX) reported Total Non-Current Liabilities of $195.9 million for Q1 2026, up 36.57% year-over-year from $143.5 million in Q1 2025, and down 2.13% quarter-over-quarter from $200.2 million in Q4 2025.
Macrogenics (MGNX) Total Non-Current Liabilities (2012 - 2026) Analysis & Trends
Macrogenics (MGNX) has 14 years of Total Non-Current Liabilities data on file, last reported at $195.9 million in Q1 2026.
- Total Non-Current Liabilities for Q1 2026 came in at $195.9 million, up 36.57% year-over-year; the trailing twelve-month figure through Mar 2026 was $195.9 million (up 36.57% YoY), and the FY2025 annual result was $200.2 million, up 39.39% from the prior year.
- Total Non-Current Liabilities eased to $195.9 million in Q1 2026 per MGNX's latest filing, from $200.2 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $234.0 million in Q1 2023 and troughed at $72.1 million in Q3 2022.
- A 5-year average of $150.0 million and a median of $143.6 million in 2024 frame the typical range for Total Non-Current Liabilities.
- The sharpest annual moves came in 2023 and 2024: Total Non-Current Liabilities jumped 151.66% in 2023, then slumped 39.36% in 2024.
- A 5-year view of Total Non-Current Liabilities shows it stood at $138.2 million in 2022, then advanced by 5.32% to $145.5 million in 2023, then slipped by 1.32% to $143.6 million in 2024, then soared by 39.39% to $200.2 million in 2025, then retreated by 2.13% to $195.9 million in 2026.
- Business Quant data shows MGNX's Total Non-Current Liabilities at $195.9 million in Q1 2026, $200.2 million in Q4 2025, and $202.4 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 42,980.09 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 11.03 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 95.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 5.87 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 64.76 Mn |
| 10 | Macrogenics | 260.14 Mn | 193.63 Mn | - | 195.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 195.95 Mn |
| Dec 31, 2025 | 200.20 Mn |
| Sep 30, 2025 | 202.43 Mn |
| Jun 30, 2025 | 197.13 Mn |
| Mar 31, 2025 | 143.48 Mn |
| Dec 31, 2024 | 143.63 Mn |
| Sep 30, 2024 | 144.17 Mn |
| Jun 30, 2024 | 143.06 Mn |
| Mar 31, 2024 | 141.87 Mn |
| Dec 31, 2023 | 145.55 Mn |
| Sep 30, 2023 | 145.73 Mn |
| Jun 30, 2023 | 133.85 Mn |
| Mar 31, 2023 | 233.97 Mn |
| Dec 31, 2022 | 138.20 Mn |
| Sep 30, 2022 | 72.13 Mn |
| Jun 30, 2022 | 75.30 Mn |
| Mar 31, 2022 | 92.97 Mn |
| Dec 31, 2021 | 95.37 Mn |
| Sep 30, 2021 | 100.46 Mn |
| Jun 30, 2021 | 106.61 Mn |